126,040 Shares in MannKind Co. (MNKD) Acquired by Element Capital Management LLC

Element Capital Management LLC bought a new position in shares of MannKind Co. (NASDAQ:MNKD) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 126,040 shares of the biopharmaceutical company’s stock, valued at approximately $287,000. Element Capital Management LLC owned 0.09% of MannKind as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the stock. BlackRock Inc. grew its holdings in MannKind by 82.8% during the fourth quarter. BlackRock Inc. now owns 3,534,811 shares of the biopharmaceutical company’s stock worth $8,201,000 after acquiring an additional 1,600,802 shares during the period. Geode Capital Management LLC grew its holdings in MannKind by 14.7% during the fourth quarter. Geode Capital Management LLC now owns 551,568 shares of the biopharmaceutical company’s stock worth $1,279,000 after acquiring an additional 70,542 shares during the period. Tibra Equities Europe Ltd acquired a new stake in MannKind during the first quarter worth about $608,000. Dupont Capital Management Corp grew its holdings in MannKind by 31.3% during the first quarter. Dupont Capital Management Corp now owns 265,000 shares of the biopharmaceutical company’s stock worth $604,000 after acquiring an additional 63,100 shares during the period. Finally, Schwab Charles Investment Management Inc. grew its holdings in MannKind by 31.7% during the first quarter. Schwab Charles Investment Management Inc. now owns 248,110 shares of the biopharmaceutical company’s stock worth $566,000 after acquiring an additional 59,682 shares during the period. 19.42% of the stock is currently owned by hedge funds and other institutional investors.

Shares of MNKD opened at $2.01 on Friday. The company has a current ratio of 0.43, a quick ratio of 0.39 and a debt-to-equity ratio of -0.43. MannKind Co. has a 12 month low of $1.09 and a 12 month high of $6.96. The company has a market capitalization of $268.85 million, a price-to-earnings ratio of -1.73 and a beta of 2.79.

MannKind (NASDAQ:MNKD) last issued its quarterly earnings data on Wednesday, May 9th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.02). The business had revenue of $3.47 million during the quarter, compared to the consensus estimate of $3.53 million. During the same quarter in the prior year, the firm posted ($0.17) earnings per share. research analysts anticipate that MannKind Co. will post -0.83 earnings per share for the current year.

MNKD has been the topic of several analyst reports. Zacks Investment Research raised MannKind from a “hold” rating to a “buy” rating and set a $2.75 target price on the stock in a report on Thursday, March 29th. HC Wainwright set a $5.00 target price on MannKind and gave the stock a “buy” rating in a report on Thursday, May 10th. Maxim Group lowered MannKind from a “hold” rating to a “sell” rating and set a $1.00 target price on the stock. in a report on Wednesday, February 28th. BidaskClub lowered MannKind from a “sell” rating to a “strong sell” rating in a report on Wednesday, April 4th. Finally, ValuEngine raised MannKind from a “strong sell” rating to a “sell” rating in a report on Wednesday, May 2nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $2.76.

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients. It offers Afrezza, a dry powder formulation of human insulin that controls high blood sugar in adults with type 1 and type 2 diabetes in the United States.

Want to see what other hedge funds are holding MNKD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MannKind Co. (NASDAQ:MNKD).

Institutional Ownership by Quarter for MannKind (NASDAQ:MNKD)

Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply